Horizon Pharma Inc. (NASDAQ:HZNP)‘s stock had its “outperform” rating reiterated by equities researchers at BMO Capital Markets in a report released on Monday. They presently have a $29.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would indicate a potential upside of 37.77% from the stock’s current price.

HZNP has been the subject of a number of other reports. Morgan Stanley set a $24.00 price objective on Horizon Pharma and gave the company a “hold” rating in a report on Monday, September 12th. Mizuho restated a “buy” rating on shares of Horizon Pharma in a report on Thursday, September 29th. Piper Jaffray Cos. restated an “overweight” rating and issued a $33.00 price objective (down from $34.00) on shares of Horizon Pharma in a report on Wednesday, August 10th. Citigroup Inc. increased their price objective on Horizon Pharma from $18.00 to $21.00 and gave the company a “neutral” rating in a report on Tuesday, August 9th. Finally, Goldman Sachs Group Inc. restated a “buy” rating and issued a $27.00 price objective on shares of Horizon Pharma in a report on Thursday, September 8th. Two analysts have rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $29.62.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Shares of Horizon Pharma (NASDAQ:HZNP) opened at 21.05 on Monday. Horizon Pharma has a one year low of $13.05 and a one year high of $23.44. The company’s market capitalization is $3.39 billion. The stock has a 50 day moving average price of $18.75 and a 200-day moving average price of $18.60.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported $0.70 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.07. The business earned $273.70 million during the quarter, compared to the consensus estimate of $270.04 million. Horizon Pharma had a positive return on equity of 22.73% and a negative net margin of 1.34%. Horizon Pharma’s quarterly revenue was up 20.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.70 earnings per share. On average, equities research analysts expect that Horizon Pharma will post $2.02 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this piece can be accessed at http://www.dailypolitical.com/2016/11/30/horizon-pharma-inc-hznp-rating-reiterated-by-bmo-capital-markets.html.

A number of institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new position in shares of Horizon Pharma during the third quarter valued at $112,000. Societe Generale acquired a new position in shares of Horizon Pharma during the second quarter valued at $117,000. SG Americas Securities LLC acquired a new position in shares of Horizon Pharma during the second quarter valued at $117,000. Nuveen Asset Management LLC acquired a new position in shares of Horizon Pharma during the second quarter valued at $176,000. Finally, Profund Advisors LLC acquired a new position in shares of Horizon Pharma during the second quarter valued at $194,000. 86.91% of the stock is currently owned by institutional investors and hedge funds.

About Horizon Pharma

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

5 Day Chart for NASDAQ:HZNP

Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.